Novelion Therapeutics Inc (NVLN)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Mary J. Szela
Employees:
109
C/O NORTON ROSE FULBRIGHT, 1800 - 510 WEST GEORGIA STREET, VANCOUVER, CANADA V6B 0M3
(877) 764-3131

*** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

Novelion Therapeutics, Inc. develops and markets ocular products. It is engaged in developing new standards of care for individuals living with rare diseases. The company is headquartered in Vancouver, Canada.

Data derived from most recent annual or quarterly report
Market Cap 13.342 Million Shares Outstanding19.62 Million Avg 30-day Volume 207.024 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-1.67
Price to Revenue0.0 Debt to Equity-3.0219 EBITDA-15.128 Million
Price to Book Value0.0 Operating Margin-32.9853 Enterprise Value0
Current Ratio0.24 EPS Growth0.178 Quick Ratio0.178
1 Yr BETA 0.2599 52-week High/Low 0.0 / Profit Margin-79.4085
Operating Cash Flow Growth53.3696 Altman Z-Score0.0 Free Cash Flow to Firm -1.959 Million

Are you looking for these stocks instead?

View SEC Filings from NVLN instead.

View recent insider trading info

Funds Holding NVLN (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding NVLN

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Events (8k)

  • 8-K: filed on 2020-07-14:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2020-06-12:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2020-01-21:
    Item 1.03: Bankruptcy or Receivership
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2020-01-10:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2019-12-11:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2019-11-05:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 5.07: Submission of Matters to a Vote of Security Holders
    Item 8.01: Other Events
  • 8-K: filed on 2019-10-08:
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 8.01: Other Events
  • 8-K: filed on 2019-09-27:
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2019-09-25:
    Item 1.03: Bankruptcy or Receivership
    Item 2.01: Completion of Acquisition or Disposition of Assets
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 8.01: Other Events
  • 8-K: filed on 2019-09-11:
    Item 1.03: Bankruptcy or Receivership
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 8.01: Other Events
  • Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    BROADFIN HEALTHCARE MASTER FUND LTD

    BROADFIN CAPITAL, LLC

    KOTLER KEVIN

    • 10% Owner
    2,541,222 2020-01-09 0

    STONEPINE CAPITAL, L.P.

    • 10% Owner
    3,909,207 2019-12-10 0

    PRICE MICHAEL DENNIS CHIEF FINANCIAL OFFICER

    • Officer
    14,111 2019-09-24 0

    CHAN BARBARA Y SEE REMARKS

    • Officer
    No longer subject to file 2019-09-24 0

    HARSHBARGER BENJAMIN SEE REMARKS

    • Officer
    3,683 2019-05-09 0

    LOUIS ROGER SEE REMARKS

    • Officer
    1,162 2019-05-09 0

    BUONO LINDA SR. VP, HUMAN RESOURCES

    • Officer
    570 2019-05-09 0

    HACKMAN JEFFREY C.O.O. AND INTERIM C.E.O.

    • Officer
    110,351 2018-11-01 0

    CORRIGAN MARK

    • Director
    0 2018-08-09 0

    THOMAS JOHN C

    • Director
    0 2018-08-09 0

    SABBA STEPHEN L

    • Director
    0 2018-08-09 0

    BRUHN SUZANNE LOUISE

    • Director
    0 2018-08-09 0

    ORLOFF JOHN J

    • Director
    0 2018-08-09 0

    STERN DONALD K

    • Director
    0 2018-08-09 0

    DIPAOLO MARK

    • Director
    0 2018-08-09 0

    STEWART MURRAY EXECUTIVE VICE PRESIDENT, R&D

    • Officer
    0 2018-02-12 0

    ARYEH JASON

    • Director
    392,733 2017-05-15 0

    PERRY GREGORY D SEE REMARKS

    • Officer
    1,683 2017-05-09 0

    SZELA MARY T CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    4,384 2017-05-09 0

    SMITH SANDFORD D

    • Director
    900 2017-01-27 0

    COX GEOFFREY F

    • Director
    0 2016-12-22 0

    VANLENT ANNE

    • Director
    0 2016-12-22 0

    PLUTZKY JORGE MD

    • Director
    0 2016-12-22 0

    KOTLER KEVIN

    • Director
    • 10% Owner
    0 2016-12-22 0

    MENES REMI A SEE REMARKS

    • Officer
    0 2016-12-22 0

    KOZARICH JOHN W

    • Director
    0 2016-06-17 0

    MECKLER JEFFREY A

    • Director
    0 2016-06-17 0

    IBBOTT WILLIAM GLEN SVP, FINANCE & CFO

    • Officer
    0 2016-06-17 0

    JANES LANA ELIZABETH SR. VICE PRES. - SEE REMARKS

    • Officer
    0 2016-06-17 0

    ASSALY DORI CHRISTINE SVP, LEGAL & CORP. SECY.

    • Officer
    0 2016-06-17 0

    AEGERION PHARMACEUTICALS, INC.

    • 10% Owner
    0 2016-06-14 0

    AXIAL CAPITAL MANAGEMENT, LLC

    ANDERSEN MARC

    ASSOULINE, ELIAV

    • 10% Owner
    0 2015-06-16 0

    AXIAL CAPITAL MASTER, L.P.

    • 10% Owner
    0 2015-06-16 0

    NB PUBLIC EQUITY K/S

    SCHONHARTING FLORIAN

    • 10% Owner
    6,447,626 2014-07-11 0

    AUXILIUM PHARMACEUTICALS INC

    • 10% Owner
    0 2014-06-25 0

    LUSSOW ALEXANDER R SR. VP, BUS. DEV. & COMM. OP.

    • Officer
    0 2013-11-22 0

    ANIDO VICENTE JR

    • Director
    29,500 2013-07-15 0

    JAGPAL SUKHI CHIEF FINANCIAL OFFICER

    • Officer
    101,200 2013-07-15 0

    LUPINI LINDA SENIOR VP, HR & ORG. DEV.

    • Officer
    15,000 2012-08-13 0

    CORMATRIX CARDIOVASCULAR INC

    • Director
    0 2012-07-10 0

    CLARKE C BOYD

    • FORMER DIRECTOR
    No longer subject to file 2012-07-09 0

    MULLER CHRISTOPHER A. SEE REMARKS

    • Officer
    0 2012-04-16 0

    BUTCHOFSKY ROBERT PRESIDENT AND CEO

    • Officer
    • Director
    168,847 2012-03-20 0

    CADDEN SUZANNE SVP, DEVELOPMENT

    • Officer
    0 2011-09-14 0

    NB PUBLIC EQUITY K/S

    SCHONHARTING FLORIAN

    MADSEN CORA

    • 10% Owner
    7,397,626 2011-08-30 0

    NB PUBLIC EQUITY K/S

    HANSEN CHRISTIAN

    SCHONHARTING FLORIAN

    • 10% Owner
    7,527,613 2011-08-29 0

    FALBERG KATHRYN E

    • Director
    0 2011-05-26 0

    CARTER BRUCE L A

    • Director
    0 2011-05-26 0

    TURNER JOSEPH L

    • Director
    0 2011-05-26 0

    CROSSGROVE PETER A

    • Director
    0 2011-05-26 0

    WOOD JACK

    • Director
    0 2011-05-26 0

    MASSEY IAN J

    • Director
    0 2011-05-26 0

    NELSON CAMERON SENIOR VP, FINANCE AND CFO

    • Officer
    125,000 2011-05-25 0

    PANIGRAHI DIPAK SVP, R&D AND CMO

    • Officer
    0 2010-05-21 0

    AXIAL CAPITAL MANAGEMENT, LLC

    • 10% Owner
    5,476,229 2010-01-29 0

    HAO YONG VICE PRESIDENT, DEVELOPMENT

    • Officer
    6,591 2009-03-11 0

    SIMONS JAMES H

    RENAISSANCE TECHNOLOGIES LLC

    • PLEASE SEE FOOTNOTE (1)PLEASE SEE FOOTNOTE (1)
    5,687,587 2009-01-30 0

    NB PUBLIC EQUITY K/S

    NB PUBLIC EQUITY KOMPLEMENTAR APS

    MADSEN CORA

    HANSEN CHRISTIAN

    SCHONHARTING FLORIAN

    • 10% Owner
    6,513,579 2009-01-30 0

    HAYES THERESE VP, INVESTOR RELATIONS

    • Officer
    No longer subject to file 2008-07-31 0

    MENDELSON ALAN C

    • Director
    No longer subject to file 2008-05-14 0

    WATTIER DANIEL J VP, MARKETING & SALES

    • Officer
    No longer subject to file 2008-03-31 0

    SCOTT E DUFF

    • Director
    No longer subject to file 2007-12-31 0

    JANA PARTNERS LLC

    • 10% Owner
    7,363,191 2007-08-07 0

    LIVINGSTON PHILIP B

    • Director
    10,000 2007-05-17 0

    HENRIKSEN RONALD D

    • Director
    0 2007-05-17 0

    O CALLAGHAN PETER J SEN. VP, CORP DEV/GEN COUNSEL

    • Officer
    0 2007-05-17 0

    DUNCAN MICHAEL R MANAGER - ATRIX OPERATIONS

    • Officer
    320,829 2006-03-13 0

    CURAUDEAU ALAIN SR. VP, PORTFOLIO & PROJ. MGMT

    • Officer
    239,449 2006-03-13 0

    LEVY JULIA

    • Director
    759,730 2006-03-13 0

    SMITH MICHAEL P VP, BUSINESS DEVELOPMENT

    • Officer
    140,000 2006-03-13 0

    GROVE JANET P VP & CORPORATE COUNSEL

    • Officer
    144,863 2006-03-13 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed
    Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    Elevate your investments